2019 journal article

Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin

JOURNAL OF VETERINARY INTERNAL MEDICINE, 33(2), 783–791.

By: B. Hallman n, M. Hauck n, L. Williams*, P. Hess n  & S. Suter n

author keywords: canine; cardiology; cardiomyopathy; chemotherapy; echocardiography; oncology
MeSH headings : Animals; Antibiotics, Antineoplastic / administration & dosage; Antibiotics, Antineoplastic / adverse effects; Antibiotics, Antineoplastic / therapeutic use; Body Weight; Cardiomyopathy, Dilated / veterinary; Cardiotoxicity / veterinary; Dog Diseases / drug therapy; Dogs; Doxorubicin / administration & dosage; Doxorubicin / adverse effects; Doxorubicin / therapeutic use; Female; Heart Diseases / chemically induced; Heart Diseases / veterinary; Incidence; Male; Neoplasms / drug therapy; Neoplasms / veterinary; Retrospective Studies; Risk Factors
TL;DR: Overall, the incidence of clinical DOX‐induced cardiotoxicity is low, but Boxers and other breeds at high risk for dilated cardiomyopathy may be at an increased risk. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (Web of Science; OpenAlex)
Source: Web Of Science
Added: April 22, 2019

BackgroundDoxorubicin (DOX) can cause cumulative cardiotoxicity in dogs, but the incidence of clinical cardiotoxicity in dogs receiving DOX has not been determined.